This cluster is a non-event for the stock, option exercises and subsequent sales by C-suite insiders are routine post-vesting liquidity events. Monitor upcoming pipeline catalysts (Week 28 EVERLAST-A data end-Q3 2026, ORKA-001 Phase 3 start 1H 2027) for actual equity-moving information.
Drug in focus
ORKA drug pipeline →ORKA-001
▲ Bullish Named in this insider cluster- Impact
- Phase
- Phase 2b
- Time to market
- If Phase 3 trials begin in 1H 2027 and run successfully, a BLA submission and potential FDA approval would likely be several years away, possibly in the 2029-2030 timeframe. The company has stated its $1.1 billion cash position funds operations through a BLA filing.
- Next catalyst
- None dated
What to watchThe key catalyst to watch is the EVERLAST-A 52-week data expected in December 2026, which will demonstrate whether ORKA-001's skin-clearing responses hold up a full year after just two doses. Strong durability would reinforce the ultra-durable dosing thesis and support the Phase 3 design. Weak durability would challenge the core value proposition. Phase 3 initiation in 1H 2027 and ORKA-002 Phase 2 data in Q1 2027 are secondary catalysts. The $1.1B cash runway removes financing overhang through a BLA filing.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 18 $113.08entry
- T+1 · 3mo ago −3.00%α −3.21% · $109.69
- T+5 · 3mo ago −9.96%α −9.76% · $101.82
- T+20 · 2mo ago −16.18%α −15.19% · $94.78
- T+60 · 6d ago −3.17%α −1.12% · $109.50
Price Chart
How similar events traded
Executive Summary
Two senior insiders at Oruka Therapeutics (CMO and General Counsel) executed large-derivative exercises and sold shares on the open market for a total of $653K in net sales in the week following Q2 2026 earnings. The sales follow option exercises, not direct bearish conviction, and represent ~0.009% of the $7.4B market cap, well below materiality thresholds. The insider cluster is a routine post-vesting pattern, not a predictive signal.
Key Financial Metrics
Key Facts
- CMO Goncalves sold ~7,000 shares for ~$784K; General Counsel Quinlan sold ~52,000 shares for ~$5.6M, both after exercising options at $0–$12.50 strike prices.
- Total open-market sales of ~$653K represent ~0.009% of Oruka's $7.4B market cap, trivial.
- Insider activity occurred 7 days after Q2 2026 earnings (consensus-beating EPS loss of $0.55 vs $0.49) following an upsized $700M April 2026 public offering; no material negative catalyst.
Financial Impact
~$6.4M in aggregate insider sales (including option exercises), but open-market net sales of $653K, immaterial relative to $7.4B market cap and $1.1B cash balance.
Risk Factors
- Insider sales could pick up in volume or frequency ahead of clinical readouts, signaling reduced conviction.
- Pre-commercial biotech's sole catalyst is pipeline data, any negative readout would be highly material.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ORKA-1787004617759 |
Track record
40 reports on ORKA
7 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +80.05% at T+60 after the Jun 1, 2026 report. 11 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $102.46 Now $99.24 −3.14% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry price pending
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $106.15 Now $99.24 −6.51% settles Dec 15
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $104.89 Now $99.24 −5.39% settles Dec 15
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $109.50 Now $99.24 −9.37% settles Dec 9
- Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 3/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
- Oct 26, 202621d ago 8-K Bullish 6/10 Entry $90.33 Now $99.24 +9.86% settles Nov 23
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers